|
|
 |
|
|
Research Fund |
Status |
NIH SBIR Phase I, “Immunoassays for metabolites of AA
epoxygenases”, 6/1/98–1/31/99. |
Completed |
NIH SBIR Phase I, “Mutagenicity/genotoxicity assays with
endogenous PGHS-2”, 8/1/99 7/31/00. |
Completed |
NIH SBIR Phase I, “Microarrays of X. laevis genes: A tool for
molecular toxicology”, 2/1/01-10/31/01. |
Completed |
NIH R15 grant, "Role of cytochrome P450 in isoflavone
metabolism" 9/30/99-9/29/03. |
Completed |
NIH SBIR Phase II, “Immunoassays for metabolites of AA
epoxygenases”, 3/15/00–3/13/04. |
Completed |
NIH SBIR Phase I, “Targeted antibody microarrays: A tool for
toxicoproteomics”, 6/1/03-3/30/04. |
Completed |
NIH SBIR Phase II, “Mutagenicity/genotoxicity assays with PGHS-
2”, 9/30/01–6/30/04. |
Completed |
Michigan Life Science Corridor Fund partner company “The
mechanism of eukaryotic arsenic transport and resistance”, 1/1/01-
12/31/04. |
Completed |
NIH SBIR Phase II, “Microarrays of X. laevis genes: A tool for
molecular toxicology”, 9/19/03-8/31/06. |
Active |
NIH SBIR Phase I “Fetal alcohol syndrome biomarkers by antibody
microarray” 9/15/03–8/31/06. |
Active |
STTR Phase I “A molecular signature of cell invasion in breast
cancer”, 3/1/04–2/28/07. |
Active |
SBIR Phase II “Targeted antibody microarrays: a tool for
toxicoproteomics”. 9/1/05-8/31/07. |
Active |
SBIR Phase I “Antibody and protein microarrays for early cancer
detection”. 10/1/05-3/31/2006. |
Active |
|
|
| | 
